The challenge of CDG diagnosis

R. Francisco, D. Marques-da-Silva, S. Brasil, C. Pascoal, V. dos Reis Ferreira, Eva Morava-Kozicz, J. Jaeken

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases that currently includes some 130 different types. CDG diagnosis is a challenge, not only because of this large number but also because of the huge clinical heterogeneity even within a number of CDG. In addition, the classical screening test, serum transferrin isoelectrofocusing, is only positive in about 60% of CDG, and can even become negative in some CDG particularly in PMM2-CDG, the most frequent N-glycosylation defect. In order to facilitate CDG diagnosis, we hereby provide some practical tools: (1) a list of clinical features strongly suggestive of a distinctive CDG; (2) a table of clinical, biochemical and laboratory findings reported in CDG, arranged per organ/system; (3) an overview of the affected organs/systems in each CDG; and (4) a diagnostic decision tree in face of a patient with a suspicion of CDG. Most important is to keep in mind a CDG in any unexplained syndrome, in particular when there is neurological involvement. This mini-review enumerates clinical and biochemical hallmarks of these diseases and the biochemical and genetic testing available, and provides an updated list and information on identified CDG. The main aim is to act as a CDG diagnosis simplified guide for healthcare professionals and, additionally, as an awareness and lobbying tool to help in the effectiveness and promptness of CDG diagnosis.

Original languageEnglish (US)
JournalMolecular Genetics and Metabolism
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Congenital Disorders of Glycosylation
Glycosylation
Lobbying
Decision Trees
Inborn Genetic Diseases

Keywords

  • CDG
  • Diagnosis
  • Molecular testing
  • MS
  • NGS
  • Whole Exome Sequencing

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Cite this

Francisco, R., Marques-da-Silva, D., Brasil, S., Pascoal, C., dos Reis Ferreira, V., Morava-Kozicz, E., & Jaeken, J. (Accepted/In press). The challenge of CDG diagnosis. Molecular Genetics and Metabolism. https://doi.org/10.1016/j.ymgme.2018.11.003

The challenge of CDG diagnosis. / Francisco, R.; Marques-da-Silva, D.; Brasil, S.; Pascoal, C.; dos Reis Ferreira, V.; Morava-Kozicz, Eva; Jaeken, J.

In: Molecular Genetics and Metabolism, 01.01.2018.

Research output: Contribution to journalArticle

Francisco, R, Marques-da-Silva, D, Brasil, S, Pascoal, C, dos Reis Ferreira, V, Morava-Kozicz, E & Jaeken, J 2018, 'The challenge of CDG diagnosis', Molecular Genetics and Metabolism. https://doi.org/10.1016/j.ymgme.2018.11.003
Francisco R, Marques-da-Silva D, Brasil S, Pascoal C, dos Reis Ferreira V, Morava-Kozicz E et al. The challenge of CDG diagnosis. Molecular Genetics and Metabolism. 2018 Jan 1. https://doi.org/10.1016/j.ymgme.2018.11.003
Francisco, R. ; Marques-da-Silva, D. ; Brasil, S. ; Pascoal, C. ; dos Reis Ferreira, V. ; Morava-Kozicz, Eva ; Jaeken, J. / The challenge of CDG diagnosis. In: Molecular Genetics and Metabolism. 2018.
@article{c7680a189b2e40d4b3bd6439c49e8b9c,
title = "The challenge of CDG diagnosis",
abstract = "Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases that currently includes some 130 different types. CDG diagnosis is a challenge, not only because of this large number but also because of the huge clinical heterogeneity even within a number of CDG. In addition, the classical screening test, serum transferrin isoelectrofocusing, is only positive in about 60{\%} of CDG, and can even become negative in some CDG particularly in PMM2-CDG, the most frequent N-glycosylation defect. In order to facilitate CDG diagnosis, we hereby provide some practical tools: (1) a list of clinical features strongly suggestive of a distinctive CDG; (2) a table of clinical, biochemical and laboratory findings reported in CDG, arranged per organ/system; (3) an overview of the affected organs/systems in each CDG; and (4) a diagnostic decision tree in face of a patient with a suspicion of CDG. Most important is to keep in mind a CDG in any unexplained syndrome, in particular when there is neurological involvement. This mini-review enumerates clinical and biochemical hallmarks of these diseases and the biochemical and genetic testing available, and provides an updated list and information on identified CDG. The main aim is to act as a CDG diagnosis simplified guide for healthcare professionals and, additionally, as an awareness and lobbying tool to help in the effectiveness and promptness of CDG diagnosis.",
keywords = "CDG, Diagnosis, Molecular testing, MS, NGS, Whole Exome Sequencing",
author = "R. Francisco and D. Marques-da-Silva and S. Brasil and C. Pascoal and {dos Reis Ferreira}, V. and Eva Morava-Kozicz and J. Jaeken",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ymgme.2018.11.003",
language = "English (US)",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The challenge of CDG diagnosis

AU - Francisco, R.

AU - Marques-da-Silva, D.

AU - Brasil, S.

AU - Pascoal, C.

AU - dos Reis Ferreira, V.

AU - Morava-Kozicz, Eva

AU - Jaeken, J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases that currently includes some 130 different types. CDG diagnosis is a challenge, not only because of this large number but also because of the huge clinical heterogeneity even within a number of CDG. In addition, the classical screening test, serum transferrin isoelectrofocusing, is only positive in about 60% of CDG, and can even become negative in some CDG particularly in PMM2-CDG, the most frequent N-glycosylation defect. In order to facilitate CDG diagnosis, we hereby provide some practical tools: (1) a list of clinical features strongly suggestive of a distinctive CDG; (2) a table of clinical, biochemical and laboratory findings reported in CDG, arranged per organ/system; (3) an overview of the affected organs/systems in each CDG; and (4) a diagnostic decision tree in face of a patient with a suspicion of CDG. Most important is to keep in mind a CDG in any unexplained syndrome, in particular when there is neurological involvement. This mini-review enumerates clinical and biochemical hallmarks of these diseases and the biochemical and genetic testing available, and provides an updated list and information on identified CDG. The main aim is to act as a CDG diagnosis simplified guide for healthcare professionals and, additionally, as an awareness and lobbying tool to help in the effectiveness and promptness of CDG diagnosis.

AB - Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases that currently includes some 130 different types. CDG diagnosis is a challenge, not only because of this large number but also because of the huge clinical heterogeneity even within a number of CDG. In addition, the classical screening test, serum transferrin isoelectrofocusing, is only positive in about 60% of CDG, and can even become negative in some CDG particularly in PMM2-CDG, the most frequent N-glycosylation defect. In order to facilitate CDG diagnosis, we hereby provide some practical tools: (1) a list of clinical features strongly suggestive of a distinctive CDG; (2) a table of clinical, biochemical and laboratory findings reported in CDG, arranged per organ/system; (3) an overview of the affected organs/systems in each CDG; and (4) a diagnostic decision tree in face of a patient with a suspicion of CDG. Most important is to keep in mind a CDG in any unexplained syndrome, in particular when there is neurological involvement. This mini-review enumerates clinical and biochemical hallmarks of these diseases and the biochemical and genetic testing available, and provides an updated list and information on identified CDG. The main aim is to act as a CDG diagnosis simplified guide for healthcare professionals and, additionally, as an awareness and lobbying tool to help in the effectiveness and promptness of CDG diagnosis.

KW - CDG

KW - Diagnosis

KW - Molecular testing

KW - MS

KW - NGS

KW - Whole Exome Sequencing

UR - http://www.scopus.com/inward/record.url?scp=85056729645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056729645&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2018.11.003

DO - 10.1016/j.ymgme.2018.11.003

M3 - Article

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

ER -